Questions? Contact us.

sidebar-facebook

At Diplomat, we serve our patients with immune globulin products for treatment of primary immune deficiencies and autoimmune-related disorders. We carry a number of major brands and ship them via express delivery anywhere in the United States. Moreover, our clinicians are available to assist you 24 hours per day, 7 days per week.

Intravenous Immune Globulin (IVIg)

  • Bivigam® [bivigam.com]

    Form Liquid
    Distributor Biotest Pharmaceuticals
    Route of administration Intravenous
    FDA indication PIDD. Package Insert
    pH (after reconstitution) 4.0–4.6
    Concentration 10%
    IgA content ≤ 200 μg/mL
    % IgG ≥96%
    Na content (at 5% concentration) 0.100–0.140 M sodium chloride
    Diluent N/A
    Osmolality (mOsm/L) ≤ 510 mOsm/kg
    Initial infusion rate (IV only) 0.5 mg/kg/min for the first 10 minutes
    Sugar content No sugar added
    Shelf life Until expiration date on vial packaging at 2 to 8°C (36 to 46°F)
    Storage requirements Refrigerate between 2 to 8°C (36 to 46°F). Do not freeze or heat.
    Patient support/assistance program Bivigam Cares
  • Carimune® NF [carimunenf.com]

    Form Lyophilized
    Distributor CSL Behring
    Route of administration Intravenous
    FDA indication PIDD, ITP. Package Insert
    pH (after reconstitution) 6.6 ± 0.2
    Concentration 3, 6, 9 or 12%
    IgA content 720 μg/mL
    % IgG ≥96%
    Na content (at 5% concentration) <20 mg NaCl/gm protein
    Diluent Sterile Water, 5% Dextrose or 0.9% NaCl
    Osmolality (mOsm/L):
    • Sterile water: 192–768 (3–12%)
    • 5% dextrose: 444–1020 (3–12%)
    • 0.9% NaCl: 498–1074 (3–12%)
    Initial infusion rate See calculations in package insert
    Sugar content 1.67 gm sucrose
    Shelf life 24 months
    Storage requirements Room temperature: up to 30°C (86°F)
    Flushing compatibility Saline or dextrose
    Patient support/assistance programs CSL Behring Patient Assistance Program, CSL Behring Assurance Program
    Other websites TreatingPI.com
  • Flebogamma® 5% DIF [grifols.com]

    Form Liquid
    Distributor Grifols
    Route of administration Intravenous
    FDA indication PIDD. Package Insert
    pH (after reconstitution) 5 – 6
    Concentration 5%
    IgA content <50 μg/mL
    % IgG ≥97%
    Na content (at 5% concentration) <3.2 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 240 – 370
    Initial infusion rate Initial rate of 0.01 mL/kg body weight/min. If tolerated during first 30 minutes, can be gradually increased to a max of 0.1 mL/kg/min.
    Sugar content 5 g D-sorbitol (as stabilizer) in 100 mL of water for injection
    Shelf life 24 months
    Storage requirements Room temperature: 2–25°C (36 to 77°F). Do not freeze.
    Flushing compatibility Saline or dextrose
  • Flebogamma® 10% DIF [grifols.com]

    Form Liquid
    Distributor Grifols
    Route of administration Intravenous
    FDA indication PIDD. Package Insert
    pH (after reconstitution) 5 – 6
    Concentration 10%
    IgA content <100 μg/mL
    % IgG ≥97%
    Na content (at 5% concentration) Trace amounts
    Diluent N/A
    Osmolality (mOsm/L) 240 – 370
    Initial infusion rate 0.01 mL/kg/min (1 mg/kg/min). If tolerated, increase to 0.08 mL/kg/min (8 mg/kg/min).
    Sugar content 5 g D-sorbitol (as stabilizer) in 100 mL of water for injection
    Shelf life 24 months
    Storage requirements Room temperature: 2–25°C (36 to 77°F). Do not freeze.
    Flushing compatibility Saline or dextrose
  • Gammagard® S/D IgA <1 μg/mL [gammagard.com]

    Form Lyophilized
    Distributor Baxter Healthcare
    Route of administration Intravenous
    FDA indication PIDD, ITP, CLL, Kawasaki Disease. Package Insert
    pH (after reconstitution) 6.8 ± 0.4
    Concentration 5% (for 10%, use half of supplied diluent)
    IgA content <1 μg/mL
    % IgG ≥90%
    Na content (at 5% concentration) 0.85% with 5%
    Diluent Sterile Water (96 mL for 5 gm 5%, 192 mL for 10 gm 5%)
    Osmolality (mOsm/L) 636 (5%), 1250 (10%)
    Initial infusion rate:
    • 5 solution%: 0.5 mL/kg/hr (0.8 mg/kg/min). Can gradually increase every 30 minutes to a rate of 4 mL/kg/hr.
    • 10% solution: If 4 mL/kg/hr is tolerated, can increase to 10% solution starting at 0.5 mL/kg/hr to a max of 8mL/kg/hr.
    Sugar content 20 mg/mL glucose with 5%
    Shelf life 24 months
    Storage requirements Room temperature: up to 25ºC (77ºF). Freezing should be avoided to prevent the diluent bottle from breaking.
    Flushing compatibility Saline or dextrose
    Patient support/assistance programs Gammagard Patient Support Program,MyIgSource
    Other websites ImmuneDisease.com
  • Gammagard® Liquid [gammagard.com]

    Form Liquid
    Distributor Baxter Healthcare
    Route of administration Intravenous or Subcutaneous
    FDA indication PIDD, MMN. Package Insert
    pH (after reconstitution) 4.6–5.1
    Concentration 10%
    IgA content 37 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) Non-detectable
    Diluent N/A
    Osmolality (mOsm/L) 240–300
    Initial infusion rate (IV only)
    • PIDD: 0.5 mL/kg/hr (0.8 mg/kg/min) for 30 minutes.
    • MMN: 0.5 mL/kg/hr (0.8 mg/kg/min).
    Initial infusion rate (SC only)
    • PIDD:
      • ≥40 kg body weight: 30 mL/site at 20 mL/hr/site.
      • <40kg: 20 mL/site at 15 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 12 months (at room temperature within the first 24 months of date of manufacture).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Saline or dextrose
    Patient support/assistance programs:
    Other websites ImmuneDisease.com
  • Gammaked™ [gammaked.com]

    Form Liquid
    Distributor Kedrion Biopharma
    Route of administration Intravenous or Subcutaneous
    FDA indication PIDD, ITP, CIDP. Package Insert
    pH (after reconstitution) 4 – 4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) 1.3 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only):
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
  • Gammaplex® [gammaplex.com]

    Form Liquid
    Distributor Bio Products Laboratory
    Route of administration Intravenous
    FDA indication PIDD. Package Insert
    pH (after reconstitution) 4.8 – 5
    Concentration 5%
    IgA content <10 μg/mL
    % IgG >95%
    Na content (at 5% concentration) 0.3 g NaCl
    Diluent N/A
    Osmolality (mOsm/L) ≥240 (typically 420 – 500)
    Initial infusion rate (IV only) 0.5 mg/kg/min (0.01 mL/kg/min for 15 minutes, then gradually increase to 4mg/kg/min. (0.08 mL/kg/min).
    Sugar content 5 g D-sorbitol in 100 mL of buffer solution
    Shelf life 24 months (room temperature)
    Storage requirements Room temperature: 2–25°C (36–77°F). Do not freeze.
    Flushing compatibility Saline or dextrose
  • Gamunex®-C [gamunex-c.com]

    Form Liquid
    Distributor Grifols
    Route of administration Intravenous or Subcutaneous
    FDA indication PIDD, ITP, CIDP. Package Insert
    pH (after reconstitution) 4–4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) 1.3 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only)
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
    Patient support/assistance program Gamunex Connexions
  • Octagam® 5% [octagamus.net]

    Form Liquid
    Distributor Octapharma
    Route of administration Intravenous
    FDA indication PIDD. Package Insert
    pH (after reconstitution) 5.1 – 6
    Concentration 5%
    IgA content ≤2 μg/mL
    % IgG ≥96%
    Na content (at 5% concentration) <30 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 310–380
    Initial infusion rate (IV only) Initial rate of 0.5 mg/kg/min.
    Sugar content 100 mg/mL maltose*
    Shelf life 24 months
    Storage requirements Room temperature: 2–25°C (36–77°F). Do not freeze.
    Flushing compatibility Saline or Dextrose

    * Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ] or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in Octagam liquid as glucose. This has resulted in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering Octagam liquid, the measurement of blood glucose must be done with a glucose-specific method. The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products.

    Octagam® 10% [octagamus.net]

    Form Liquid
    Distributor Octapharma
    Route of administration Intravenous
    FDA indication Chronic immune thrombocytopenic purpura (ITP)
    pH (after reconstitution) 4.5–5
    Concentration 10%
    IgA content ≤2 μg/mL
    % IgG ≥96%
    Na content (at 5% concentration) <30 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 310–380 mOsmol/kg
    Initial infusion rate 1.0 mg/kg/min (0.01 mL/kg/min)
    Maintenance Infusion Rate (if tolerated) Up to 12.0 mg/kg/min (Up to 0.12 mL/kg/min)
    Sugar content 90 mg/mL maltose*
    Shelf life 24 months (refrigerated). Within the first 12 months of its shelf-life, the product may be stored up to 6 months at ≤ +25°C (77°F).
    Storage requirements Room temperature: 2–25°C (36–77°F). Do not freeze.

    * Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ] or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in Octagam liquid as glucose. This has resulted in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering Octagam liquid, the measurement of blood glucose must be done with a glucose-specific method. The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products.

  • Privigen® [privigen.com]

    Form Liquid
    Distributor CSL Behring
    Route of administration Intravenous
    FDA indication PIDD, ITP. Package Insert
    pH (after reconstitution) 4.6 – 5
    Concentration 10%
    IgA content <25 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) Trace amounts
    Diluent N/A
    Osmolality (mOsm/L) 320
    Initial infusion rate (IV only):
    • PIDD: Initial rate of 0.005 mL/kg/min. If tolerated, increase gradually to 0.08 mL/kg/min.
    • ITP: Initial rate of 0.005 mL/kg/min. If tolerated, increase gradually to 0.04 mL/kg/min.
    Sugar content No added sugars
    Shelf life 36 months (room temperature)
    Storage requirements Room temperature: up to 25°C (77°F). Do not freeze. Protect from light.
    Flushing compatibility Saline or Dextrose
    Patient assistance/support programs CSL Behring Patient Assistance Program, CSL Behring Assurance Program
    Other websites TreatingPI.com, IgIQ

Subcutaneous Immune Globulin (SCIg)

  • Cuvitru™ [cuvitru.com]

    Form Liquid
    Distributor Baxalta/Shire
    Route of administration Subcutaneous
    FDA Indication PIDD. Package Insert
    pH 4.6 to 5.1
    Concentration 20%
    IgA content 80 mcg/mL
    % IgG ≥98%
    Na content Non-detectable
    Diluent N/A
    Osmolality (mOsm/L) 280-292
    Initial infusion rate Do not administer intravenously or intramuscularly. For the first two infusions, the manufacturer’s recommended infusion rate is 10-20 mL/hr/site. For subsequent infusions, the infusion rate may be increased to 60 mL/hr/site as tolerated (e.g., 60 mL/hr/site x 2 sites = 120 mL/hr). For patients utilizing 4 infusion sites, the maximum infusion rate for all sites combined is 240 mL/hr.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 12 months (at room temperature within the first 24 months of date of manufacture).
    Storage requirements Protect from light. Store in the refrigerator (36°F to 46°F [2°C to 8°C]) for up to 36 months or at room temperature (up to 77°F [25°C]) for up to 12 months.
    Patient assistance/support programs MyIgSource.com
    Other websites ImmuneDisease.com
  • Gammagard® Liquid [gammagard.com]

    Form Liquid
    Distributor Baxter Healthcare
    Route of administration Intravenous or Subcutaneous
    FDA indication PIDD, MMN. Package Insert
    pH (after reconstitution) 4.6–5.1
    Concentration 10%
    IgA content 37 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) Non-detectable
    Diluent N/A
    Osmolality (mOsm/L) 240–300
    Initial infusion rate (IV only)
    • PIDD: 0.5 mL/kg/hr (0.8 mg/kg/min) for 30 minutes.
    • MMN: 0.5 mL/kg/hr (0.8 mg/kg/min).
    Initial infusion rate (SC only)
    • PIDD:
      • ≥40 kg body weight: 30 mL/site at 20 mL/hr/site.
      • <40kg: 20 mL/site at 15 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 12 months (at room temperature within the first 24 months of date of manufacture).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Saline or dextrose
    Patient support/assistance programs:
    Other websites ImmuneDisease.com
  • Gammaked™ [gammaked.com]

    Form Liquid
    Distributor Kedrion Biopharma
    Route of administration Intravenous or Subcutaneous
    FDA indication PIDD, ITP, CIDP. Package Insert
    pH (after reconstitution) 4 – 4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) 1.3 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only):
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
  • Gamunex®-C [gamunex-c.com]

    Form Liquid
    Distributor Grifols
    Route of administration Intravenous or Subcutaneous
    FDA indication PIDD, ITP, CIDP. Package Insert
    pH (after reconstitution) 4–4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) 1.3 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only)
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
    Patient support/assistance program Gamunex Connexions
  • Hizentra® [hizentra.com]

    Form Liquid
    Distributor CSL Behring
    Route of administration Subcutaneous
    FDA indication PIDD. Package Insert
    pH (after reconstitution) 4.6 – 5.2
    Concentration 20%
    IgA content ≤50 μg/mL
    % IgG ≥98%
    Na content (at 5% concentration) Trace
    Diluent N/A
    Osmolality (mOsm/L) N/A
    Initial infusion rate (IV only) Not for intravenous administration. Avoid injection into blood vessel. Injection sites: abdomen, thighs, upper arms, and/or lateral hip. Manufacturer recommends 15 mL volume per infusion site at a max rate of 50 mL/hr/site by infusion pump.
    Sugar content No added sugars
    Shelf life 18 months (room temperature)
    Storage requirements Room temperature: up to 25°C (77°F). Do not freeze. Protect from light.
    Patient assistance/support programs CSL Behring Patient Assistance Program, CSL Behring Assurance Program
    Other websites TreatingPI.com, IgIQ
  • HyQvia™ [HyQvia.com]

    Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
    Form
    Liquid
    Distributor Baxter Healthcare
    Route of administration Subcutaneous
    FDA indication PIDD. Package Insert
    pH
    • Immune Globulin Infusion 10% (Human): 4.6 – 5.1
    • Recombinant Human Hyaluronidase: 7.4
    Concentration 10%
    IgA content 37 μg/mL
    % IgG ≥98%
    Excipient content
    • Immune Globulin Infusion 10% (Human): Glycine (0.25M) serves as a stabilizing and buffering agent. No added sugar, sodium, or preservatives.
    • Recombinant Human Hyaluronidase: 8.5 mg/mL sodium chloride, 1.78 mg/mL, sodium phosphate dibasic dihydrate, 1.0 mg/mL human albumin, 1.0 mg/mL edentate disodium dihydrate, 0.40 mg/mL calcium chloride dihydrate, and 0.17 mg/mL sodium hydroxide added for pH adjustment. It does not contain preservatives.
    Diluent N/A
    Osmolality
    • Immune Globulin Infusion 10% (Human): 240 – 300 mOsmol/kg
    • Recombinant Human Hyaluronidase: 290 to 350 mOsm
    Initial infusion rate (SC only)
    • Administer the Recombinant Human Hyaluronidase of HYQVIA at an initial rate per site of approximately 1 to 2 mL per minute, or as tolerated.
    • Administer Immune Globulin Infusion 10% (Human) of HYQVIA at rates provided inpackage insert.
    Shelf life Up to 36 months refrigerated (36° to 46°F). Up to 3 months during the first 24 months at room temperature (77°F) from the date of manufacturing (Mfg date) printed on the carton.
    Storage requirements Refrigeration (36° to 46°F) for up to 36 months. Room temperature (up to 77°F) for up to 3 months. Do not freeze. Protect from light.
    Patient assistance/support programs MyIgSource
    Other websites ImmuneDisease.com

Twitter